Search

We report our experience in neoadjuvant breast cancer chemotherapy in a single centre between 2000 and 2011. We looked for predictive factors for response to neoadjuvant chemotherapy in the present study. A total of 110 consecutive breast cancer patients were treated with neoadjuvant chemotherapy in our centre. Pathological response was achieved in 24 HR+/HER2- (38.7%), 25 HER2+ (67.6%) and five triple-negative (45.5%) (p = 0.02) patients. No statistically significant differences were found in pathological tumour response according to T stage. The multivariate analysis revealed tumour subtype was the only associated factor for pathological response, with HER2 + tumours the best responders, OR 3.9 (1.5-9.9): 5-year DFS was 40% HER2+/no response; 78% HER2+/response; 65% HR+/HER2-/no response; 82% HR+/HER2-/response; 25% triple-negative/no response and 100% triple-negative/response. HR and HER2 status were the only prognostic factors for pathological response. pCR was correlated with survival in all tumour subtypes. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 35-year-old pregnant woman diagnosed with an adult type granulosa cell tumour (GCT) in the ovary. The patient had undergone power Doppler transabdominal ultrasound scan to project the peripheral vascularisation of the lesion and laparoscopic left adnexectomy surgery to remove the intact lesion. It also mentions that GCT adult type appears in postmenopausal and perimenopausal women with treatment option utilizing conservative surgery.